Materialise NV Reports Strong Q4 and Full Year 2025 Financial Results
- Significant Revenue Growth: Total revenue for Q4 2025 reached €70.164 million, a 6.8% increase year-over-year, demonstrating strong performance in the medical device sector, particularly with a 16.3% rise in medical segment revenue to €37.016 million, further solidifying market leadership.
- Improved Profitability: Adjusted EBITDA for Q4 2025 surged to €9.524 million from €4.306 million in the same period of 2024, reflecting successful cost control and operational efficiency, which is expected to enhance investor confidence.
- Robust Cash Flow: As of December 31, 2025, the company reported €133.918 million in cash and cash equivalents, with a net cash position improving to €70.805 million, indicating strong financial health and the ability to continue investing in R&D and market expansion.
- Optimistic Future Outlook: The company anticipates full-year revenues for 2026 to range between €273,000 and €283,000, with continued strong growth in the medical segment and a transition to a cloud-based subscription model in the software segment, showcasing proactive positioning for future market opportunities.
Trade with 70% Backtested Accuracy
Analyst Views on MTLS
About MTLS
About the author

- Earnings Announcement: Materialise is set to release its Q4 earnings on February 19 before the market opens, with expectations that the results will significantly impact stock price movements.
- Earnings Expectations: The consensus EPS estimate stands at $0.07, and achieving this target would positively reflect the company's profitability and bolster market confidence in its growth trajectory.
- Revenue Forecast: Analysts estimate revenue at $82.02 million, and meeting this expectation could enhance Materialise's competitive position in the industry while attracting increased investor interest.
- Historical Performance Review: Over the past year, Materialise has exceeded EPS estimates 50% of the time and revenue estimates 75% of the time, indicating a stable performance and growth potential in the market.
- Earnings Highlights: Materialise reported a GAAP EPS of $0.12 for Q4 2025, with revenue of $82.44 million exceeding expectations by $0.42 million and reflecting a year-over-year growth of 6.8%, indicating robust market performance.
- Adjusted EBITDA Growth: The adjusted EBITDA for Q4 increased significantly to 9,524 kEUR from 4,306 kEUR in 2024, showcasing a marked improvement in profitability and reflecting enhanced operational efficiency.
- Free Cash Flow Performance: The free cash flow for Q4 2025 was 4,511 kEUR, down from 6,218 kEUR in 2024, yet still demonstrating solid cash flow management that supports future investments.
- Future Outlook: The company anticipates full-year revenues for 2026 to grow to a range of 273,000 to 283,000 kEUR, with continued investments in its Medical and Software segments while maintaining cost discipline, projecting adjusted EBIT of 10,000 to 12,000 kEUR, indicating strong growth potential.
- Significant Revenue Growth: Total revenue for Q4 2025 reached €70.164 million, a 6.8% increase year-over-year, demonstrating strong performance in the medical device sector, particularly with a 16.3% rise in medical segment revenue to €37.016 million, further solidifying market leadership.
- Improved Profitability: Adjusted EBITDA for Q4 2025 surged to €9.524 million from €4.306 million in the same period of 2024, reflecting successful cost control and operational efficiency, which is expected to enhance investor confidence.
- Robust Cash Flow: As of December 31, 2025, the company reported €133.918 million in cash and cash equivalents, with a net cash position improving to €70.805 million, indicating strong financial health and the ability to continue investing in R&D and market expansion.
- Optimistic Future Outlook: The company anticipates full-year revenues for 2026 to range between €273,000 and €283,000, with continued strong growth in the medical segment and a transition to a cloud-based subscription model in the software segment, showcasing proactive positioning for future market opportunities.
- Q4 Revenue Growth: Total revenue for Q4 2025 reached €70,164k, a 6.8% increase year-over-year, with the Medical segment growing 16.3% to €37,016k, highlighting strong demand in the healthcare market and reinforcing the company's leadership in 3D-printed medical devices.
- Gross Margin Improvement: The gross margin for Q4 2025 rose to 58.1%, up from 55.4% in Q4 2024, reflecting successful cost control and operational efficiency, which enhances overall profitability.
- Significant Net Profit Increase: Net profit for Q4 2025 was €6,206k, a substantial rise from €2,907k in Q4 2024, indicating a marked improvement in profitability and market performance, boosting investor confidence.
- Strong Cash Reserves: As of December 31, 2025, the company reported cash and cash equivalents of €133,918k, significantly up from €102,304k in 2024, demonstrating a robust financial position that provides ample funding for future investments and innovation.
- Earnings Release Schedule: Materialise NV will release its financial results for Q4 2025 on February 19, 2026, at 2:30 a.m. ET, reflecting the company's ongoing commitment to transparency and investor communication.
- Management Conference Call: Senior management will hold a conference call on the same day at 8:30 a.m. ET to discuss the financial results, aiming to enhance investor confidence through direct communication and provide deeper financial insights.
- Webcast Access: Investors can access the live audio webcast of the conference call through the company's website, ensuring that all stakeholders can obtain key information in real-time, thereby improving information accessibility and transparency.
- Industry Leadership: As a global leader in 3D-printed medical devices and software, Materialise's financial results will provide critical data supporting its ongoing innovation and market leadership across multiple sectors, including healthcare, automotive, and aerospace.
Materialise NV: The company specializes in 3D printing software and services, holds a Zacks Rank #1, and has seen a 33.3% increase in earnings estimates over the past 60 days, with shares up 2% in three months.
Calix, Inc.: This cloud and software platform provider also has a Zacks Rank #1, with a 15.4% rise in earnings estimates in the last 60 days, and its shares increased by 12.7% over six months.
Alcoa Corporation: A producer of aluminum products, Alcoa has a Zacks Rank #1 and a 6.1% increase in earnings estimates recently, with shares soaring 44.3% in three months.
Investment Insights: Zacks Investment Research is preparing to release its top 10 stock picks for 2026, following a history of significant gains, and encourages investors to download their latest recommendations.








